AR086791A1 - POSITIVE ALLOSTERIC MODULATORS OF NICOTINIC ACETILCOLINE RECEIVER - Google Patents
POSITIVE ALLOSTERIC MODULATORS OF NICOTINIC ACETILCOLINE RECEIVERInfo
- Publication number
- AR086791A1 AR086791A1 ARP120102330A ARP120102330A AR086791A1 AR 086791 A1 AR086791 A1 AR 086791A1 AR P120102330 A ARP120102330 A AR P120102330A AR P120102330 A ARP120102330 A AR P120102330A AR 086791 A1 AR086791 A1 AR 086791A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- compounds
- alkynyl
- cyano
- alkenyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente se refiere a compuestos útiles en terapia, a composiciones que comprenden dichos compuestos, y a métodos de tratamiento de enfermedades, que comprenden la administración de dichos compuestos. Los compuestos referidos son moduladores alostéricos positivos (PAM) del receptor de acetilcolina nicotínico a7. Los compuestos son útiles para el tratamiento de la enfermedad de Alzheimer, demencia senil y otras, epilepsia, amnesia postraumática. Reivindicación 1: Un compuesto de acuerdo con la fórmula (1), donde A⁴ es C-R⁴ o N, A⁵ es C-R⁵ o N, y A⁶ es C-R⁶ o N, siempre que por lo menos uno de A⁴, A⁵ o A⁶ sea N, y no más de dos de A⁴, A⁵ y A⁶ sean N; R¹ es fenilo o heteroarilo; donde dicho fenilo o heteroarilo está opcionalmente sustituido con uno o más sustituyentes R¹¹, donde cada R¹¹ es individualmente seleccionado de alquilo C₁₋₆, halógeno, hidroxi, haloalquilo C₁₋₆, alcoxi C₁₋₆, haloalcoxi C₁₋₆, ciano, alquil C₁₋₆sulfonilo, -S(O)₂NH₂ y -NR¹²R¹³, donde R¹² y R¹³ representan, de manera independiente, hidrógeno o alquilo C₁₋₆; R² se selecciona de H, alquilo C₁₋₆, alquenilo C₂₋₆, alquinilo C₂₋₆, alcoxi C₁₋₆, halógeno y ciano; R³, R⁴, R⁵, R⁶ y R⁷ se seleccionan, de manera independiente entre sí, de H, alquilo C₁₋₆, alquenilo C₂₋₆, alquinilo C₂₋₆, alcoxi C₁₋₆, halógeno, ciano y -NR⁹R¹⁰, donde R⁹ y R¹⁰ representan, de manera independiente, hidrógeno, alquilo C₁₋₆, alquenilo C₂₋₆, alquinilo C₂₋₆, haloalquilo C₁₋₆ o fenilo; R⁸ se selecciona de H, alquilo C₁₋₆, alquenilo C₂₋₆, alquinilo C₂₋₆, alcoxi C₁₋₆, halógeno, ciano y fenilo; y una de sus sales farmacéuticamente aceptables.This refers to compounds useful in therapy, to compositions comprising said compounds, and to methods of treatment of diseases, which comprise the administration of said compounds. The referred compounds are positive allosteric modulators (PAM) of the nicotinic acetylcholine a7 receptor. The compounds are useful for the treatment of Alzheimer's disease, senile dementia and others, epilepsy, posttraumatic amnesia. Claim 1: A compound according to formula (1), wherein A⁴ is C-R⁴ or N, A⁵ is C-R⁵ or N, and A⁶ is C-R⁶ or N, provided that at least one of A⁴, A⁵ or A⁶ be N, and no more than two of A⁴, A⁵ and A⁶ are N; R¹ is phenyl or heteroaryl; wherein said phenyl or heteroaryl is optionally substituted with one or more R¹¹ substituents, where each R¹¹ is individually selected from C₁₋₆ alkyl, halogen, hydroxy, C₁₋₆ haloalkyl, C₁₋₆ alkoxy, C₁₋₆ haloalkoxy, cyano, C₁ alkyl Ulfsulfonyl, -S (O) ₂NH₂ and -NR¹²R¹³, where R¹² and R¹³ independently represent hydrogen or C₁₋₆ alkyl; R² is selected from H, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆ alkoxy, halogen and cyano; R³, R⁴, R⁵, R⁶ and R⁷ are independently selected from H, C alquilo alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆ alkoxy, halogen, cyano and -NR⁹R¹⁰, where R⁹ and R¹⁰ independently represent hydrogen, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆ haloalkyl or phenyl; R⁸ is selected from H, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆ alkoxy, halogen, cyano and phenyl; and one of its pharmaceutically acceptable salts.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA201100498 | 2011-07-01 | ||
| DKPA201100514 | 2011-07-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR086791A1 true AR086791A1 (en) | 2014-01-22 |
Family
ID=46456582
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP120102330A AR086791A1 (en) | 2011-07-01 | 2012-06-28 | POSITIVE ALLOSTERIC MODULATORS OF NICOTINIC ACETILCOLINE RECEIVER |
Country Status (3)
| Country | Link |
|---|---|
| AR (1) | AR086791A1 (en) |
| TW (1) | TW201315731A (en) |
| WO (1) | WO2013004617A1 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3345909T3 (en) * | 2015-08-19 | 2020-10-19 | Astellas Pharma Inc. | Tetrahydrooxepinopyridine compound |
| JP2019006680A (en) * | 2015-11-13 | 2019-01-17 | 国立大学法人大阪大学 | Pyrazolopyridine derivatives and uses thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9903997D0 (en) | 1999-11-03 | 1999-11-03 | Astra Ab | New compounds |
| WO2007038367A1 (en) * | 2005-09-23 | 2007-04-05 | Memory Pharmaceuticals Corporation | Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, pyrazolopyridines, isothiazolopyridines, and preparation and uses thereof |
| MX2010008714A (en) | 2008-02-07 | 2010-09-24 | Abbott Lab | Amide derivatives as positive allosteric modulators and methods of use thereof. |
-
2012
- 2012-06-28 AR ARP120102330A patent/AR086791A1/en not_active Application Discontinuation
- 2012-06-29 WO PCT/EP2012/062703 patent/WO2013004617A1/en active Application Filing
- 2012-06-29 TW TW101123404A patent/TW201315731A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2013004617A1 (en) | 2013-01-10 |
| TW201315731A (en) | 2013-04-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX367474B (en) | Bis(fluoroalkyl)-1,4-benzodiazepinone compounds as notch inhibitors. | |
| DOP2015000158A (en) | PRMT5 INHIBITORS AND THEIR USES | |
| CO6210729A2 (en) | DERIVATIVES OF SULFONIL-FENIL-2H- [1,2,4] OXADIAZOL-5-ONA PROCEDURES FOR PREPARATION AND USE AS A PHARMACEUTICAL AGENT | |
| AR088029A1 (en) | SUBSTITUTED PYRIMIDINE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND USE OF THE SAME FOR THE TREATMENT OF PAIN, CEREBROVASCULAR ACCIDENTS, EPILEPSY AND OTHER DISEASES OF THE CENTRAL NERVOUS SYSTEM | |
| AR100810A1 (en) | 3-QUINASA PHOSFATIDYLINOSITOL INHIBITORS | |
| PE20180318A1 (en) | PROCEDURE FOR PREPARING ISOQUINOLINONES AND SOLID FORMS OF ISOQUINOLINONES | |
| AR090230A1 (en) | MACROCICLIC DERIVATIVES FOR THE TREATMENT OF DISEASES | |
| PE20190446A1 (en) | POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLIN RECEPTOR M4 | |
| ECSP15012804A (en) | ALCOXYPYRAZOLES AS SOLUBLE GUANILATE CYCLASE ACTIVATORS | |
| EA201890152A1 (en) | 2,3-DIHYDRO-4H-1,3-BENZOXAZIN-4-ON DERIVATIVES AS A CHOLINERGIC MUSCARIN M1 RECEPTOR MODULATORS | |
| CO2019001181A2 (en) | Heteroarylcarboxamide compounds as ripk2 inhibitors | |
| AR087915A1 (en) | N- (3- (2-AMINO-6,6-DIFLUOR-4,4A, 5,6,7,7A-HEXAHYDRO-CYCLOPENTA- [E] [1,3] OXAZIN-4-IL) -PENYL) - AMIDAS AS INHIBITORS OF THE BACE1 | |
| AR082111A1 (en) | FUROPIRIDINES OR CONDENSED TENOPIRIDINS, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM USEFUL TO TREAT PSYCHOTIC AND CENTRAL NERVOUS SYSTEM DISORDERS, AND THE SAME PREPARATION METHOD | |
| AR092319A1 (en) | CARBAZOLS CONTAINING SULFONAMIDS AS CRYPTOPROME MODULATORS | |
| AR100806A1 (en) | 3-QUINASA PHOSFATIDYLINOSITOL INHIBITORS | |
| AR090293A1 (en) | ARILETER-BASED KINASE INHIBITORS | |
| DOP2015000002A (en) | DERIVATIVES OF AZAINDOL ACTING AS P13K INHIBITORS | |
| CR20140133A (en) | PIRIDAZINONA COMPOUNDS AND THEIR USES AS DAAO INHIBITORS | |
| AR100713A1 (en) | AMIDA DERIVATIVES OF COMPOUNDS OF 1-OXA-4,9-DIAZAESPIRO UNDECENE THAT HAVE MULTIMODAL ACTIVITY AGAINST PAIN | |
| AR092809A1 (en) | 3,5-DIAMINOPIRAZOL AS A QUINASE INHIBITOR | |
| AR100715A1 (en) | DERIVATIVES OF RENT OF COMPOUNDS 1-OXA-4,9-DIAZAESPIRO UNDECENE THAT HAVE MULTIMODAL ACTIVITY AGAINST PAIN | |
| PE20150289A1 (en) | NEW DERIVATIVES OF THENOPYRIMIDINE, PROCESSES FOR THEIR PREPARATION AND THEIR THERAPEUTIC USES | |
| AR083694A1 (en) | USE OF ACTIVE PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF PATHOLOGICAL STATES OF THE CENTRAL NERVOUS SYSTEM, PHARMACEUTICAL COMPOSITION, NEGATIVE ALLOSTERIC MODULATOR OF GABA A5, METHOD | |
| AR116424A1 (en) | SOMATOSTATIN MODULATORS AND USES OF THEM | |
| AR072803A1 (en) | TETRAHYDROCINOLINS AS INHIBITORS OF THE 11- BETA -HSD1 FOR DIABETES |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |